# Renal effects of prolonged use of furosemide in pediatric cardiac patients

**Thesis** 

Submitted for partial fulfillment of master degree in pediatrics

By

**Remon Refaat Thabet** 

(M.B.B.ch)

Cairo University

Under supervision of

Dr. Fatma Al-Zahraah Mostafa
Professor of pediatrics
Faculty of Medicine, Cairo University

Dr. Gehan Hussein Ahmed
Assistant Professor of Pediatrics
Faculty of Medicine, Cairo University

Dr. Ahmed Mohamed Badr
Lecturer of Pediatrics
Faculty of Medicine, Cairo University

Faculty of Medicine

Cairo University

2009

All words could not express my love to my *father* and my *mother* for their continuous help and self-denial.

I wish to express my hearty appreciation to my wife for her constant support.

To my sweet kids.

#### **ACKNOWLEDGEMENT**

First of all thanks to "God" for helping me to complete this study.

I am greatly honored to express my deepest gratitude and special thanks to Prof. Fatma Al-Zahraah Mostafa, Professor of pediatrics, Cairo University. She was always correcting and guiding me all the way, her scientific and moral support made it possible for this work to see the light. I am in great debt to her.

I would like to express my sincere appreciation to Dr. Gehan Hussein Ahmed, Assistant professor of Pediatrics, Cairo University, for her invaluable effort and endless help in this work. Indeed I am honored to be given the chance to gain knowledge at the hands of such supportive supervisor.

I am very grateful to Dr. Ahmed Mohamed Badr, Lecturer of Renal Diseases, Cairo University, for his valuable contributions and supports in many aspects of this work.

No words could express my thanks to my colleagues and patients for their helpful attitude.

### **Table of contents**

List of Tablesiii	
List of Figuresiv	
List of abbreviationsvi	
<b>Abstract</b>	
Introduction & Aim of the work3	
REVIEW	
CHAPTER 1: Pediatric congestive heart failure	
Definition & Causes	
CHAPTER 2: Diagnostic modalities of heart failure	
Clinical evaluation	
Laboratory tests	)
Imaging	
CHAPTER 3: Management strategy of heart failure	
General measures	
Drug therapy25	
Surgical management30	
<b>CHAPTER 4: Furosemide pharmacokinetics &amp; pharmacodynamics</b>	
Pharmacokinetics32	
Indication	
Adverse reactions34	
CHAPTER 5: Renal effects of prolonged use of diuretics	
Renal nephrocalcinosis (Definition & Causes)	
CHAPTER 6: Diagnosis of nephrocalcinosis	
Laboratory investigation	
Radiological imaging	
Management of nephrocalcinosis	
Patients & Methods 45	

Results	50
Discussion	79
Conclusion & Recommendation	84
Summary	87
References	91
Arabic summary	

### **List of Tables**

Table I	Causes of HF	Page 11
Table II	NYHA classification of HF	Page 17
Table III	ROSS classification of HF	Page 18
Table IV	Diuretic agents & dosage	Page 26
Table V	Oral digoxin dosage	Page 28
Table VI	Hypercalciuria according age	Page 39
Table VII	Nephrocalcinosis grading scale	Page 43
Table 1	Age, Wt, Wt centile of studied group	Page 54
Table 2	Sex distribution between studied group	Page 54
Table 3	Echocardiographic diagnosis of studied group	Page 56
Table 4	Stages of HF in the studied group	Page 57
Table 5	Comparison between CBC finding of the studied group	Page 58
Table 6	Comparison between electrolytes finding of the studied	Page 61
	group	
Table 7	Comparison between kidney function test finding of	Page 62
	the studied group	
Table 8	Comparison between urinary ca/cr. ratio finding of the	Page 63
	studied group	
Table 9	Nephrocalcinosis distribution among cases	Page 63
Table 10	Data of cases with &without NC	Page 73
Table 11	Comparison between data of furosemide therapy in pt.	Page 76
	with &without NC	
Table 12	Combination of furosemide with other drugs	Page 76

### **List of Figures**

Figure 1	Sex distribution between the studied groups	Page 55
Figure 2	Echocardiographic diagnosis of the studied groups	Page 56
Figure 3	Comparison between Hb levels in the studied groups	Page 59
Figure 4	Comparison between MCV levels in the studied groups	Page 59
Figure 5	Comparison between MCH levels in the studied groups	Page 60
Figure 6	Comparison between MCHC levels in the studied groups	Page 60
Figure 7	Comparison between calcium levels in the studied	Page 61
	groups	
Figure 8	Comparison between alkaline ph. levels in the studied	Page 62
	groups	
Figure 9	Comparison between urinary ca/cr. Ratios in the studied	Page 63
	groups	
Figure	Nephrocalcinosis detected by ultrasound in the studied	Page 64
10	cases	
Figure	Correlation between age of onset of furosemide therapy	Page 64
11	&serum Ca	
Figure	Correlation between age of onset of furosemide therapy	Page 65
12	&serum Na	
Figure	Correlation between furosemide dose &serum Ca	Page 65
13		
Figure	Correlation between furosemide dose &serum Na	Page 66
14		
Figure	Correlation between furosemide dose &serum	Page 66
15	phosphorus	
Figure	Correlation between furosemide dose &serum K	Page 67
16		D (5
Figure	Correlation between furosemide dose & serum alkaline	Page 67
17	ph C 1 i 1 i 1 i 1 i 1 i 1 i 1 i 1 i 1 i 1	<b>D</b> 60
Figure	Correlation between duration of furosemide therapy	Page 68
18	&serum Ca	D
Figure	Correlation between duration of furosemide therapy &serum Na	Page 68
19		Do 22 60
Figure 20	Correlation between duration of furosemide therapy &serum K	Page 69
		Daga 60
Figure 21	Correlation between furosemide dose & BUN	Page 69
Figure	Correlation between furosemide dose & creatinine	Page 70
22	Correlation between rurosennue dose & creatinine	Tage 70

Figure 23	Correlation between duration of furosemide therapy & BUN	Page 70
Figure 24	Correlation between duration of furosemide therapy & creatinine	Page 71
Figure 25	Correlation between furosemide dose &urinary ca/cr. ratio	Page 71
Figure 26	Correlation between duration of furosemide therapy &urinary ca/cr. ratio	Page 72
Figure 27	Correlation between age of onset of furosemide therapy &urinary ca/cr. ratio	Page 72
Figure 28	Sex distribution of cases with nephrocalcinosis	Page 74
Figure 29	Renal ultrasonography show nephrocalcinosis	Page 75
Figure 30	Echocardiographic diagnosis of cases with nephrocalcinosis	Page 75
Figure 31	Renal ultrasonographic finding on follow up	Page 77

#### List of abbreviations

Alk. Ph. Alkaline phosphatase
 ASD Atrial septal defect
 BUN Blood urea nitrogen

• Ca Calcium

• Ca/Cr. Calcium/Creatinine ratio

Cr. Creatinine
HF Heart failure
K Potassium
Na Sodium

NC Nephrocalcinosis

Ph. Phosphor

PDA Patent ductus arteriosus
Ps Pulmonary stenosis

• VSD Ventricular septal defect

# Abstract

# **Abstract**

Congenital heart disease in children is usually associated with congestive heart failure (CHF). The most effective medical treatment of CHF is diuretics. Prolonged use of furosemide is associated with hypercalciuria, nephrocalcinosis and renal calculi.

This study included thirty patients with CHD receiving furosemide for more than 6 months. Thirty age and sex matched normal children were included as control group. The two studied groups were subjected to full history taking, general and local cardiac examination, laboratory investigations (CBC, serum Na, K, Ca, Ph, alkaline phosphatase, BUN, creatinine and calcium/creatinine ratio) and renal ultrasonography.

Nephrocalcinosis was detected in 5 (16.7%) patients. Urinary calcium/creatinine ratio was higher than normal in one case only. In conclusion, prolonged furosemide therapy could induce nephrocalcinosis.

Renal ultrasonography is a useful and non invasive method for nephrocalcinosis detection. Periodic renal ultrasonography is recommended for patients with prolonged furosemide therapy.

### **Keyword:**

Heart failure, furosemide, nephrocalcinosis. abstract& introduction

# Introduction

# **Introduction**

Heart failure is a complex syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the heart to function as a pump to support a physiological circulation. The syndrome of heart failure is characterized by symptoms such as breathlessness and fatigue, and signs such as fluid retention.

There is no single diagnostic test for heart failure, and diagnosis relies on clinical judgment based on a combination of history, physical examination and appropriate investigations (Mike Pearson., et al 2003).

Diuretics as furosemide remain the principal therapeutic agent to control pulmonary and systemic venous congestion (Sophia Antipolis., 2005).

Prolonged use of furosemide induces hypercalciuria and nephrocalcinosis (Alon et al., 1997).

Nephrocalcinosis may be detected by renal Ultrasonography in high risk infants such as those requiring prolonged furosemide therapy. Renal calcification during infancy is often asymptomatic. Gross or microscopic hematuria and increase in blood pressure may be present (Schell-Feith et al., 2000).

Renal calcification were considered an uncommon finding in children for many years, especially when radiographic detection was the mean of detection. Since the introduction of ultrasonic imaging, renal calcifications have been detected at early ages (Alon et al., 1995).

Other side effects of furosemide therapy include hypokalemia (Chvilicek et al., 1995), hypomagnesemia, hyperglycemia (Colin et al., 1999) and hyponatremia (Jackson et al., 2001).

# Aim of the work

The aim of this study is to detect renal effects of prolonged use of furosemide, for more than 6 months, on cardiac pediatric patients as assessed by laboratory and sonographic examinations correlating these changes with age, sex, dose and duration of therapy as well as stage of heart failure. Early detection of deleterious effects (especially nephrocalcinosis) is mandatory to prevent their progression by replacing furosemide with another diuretic.